Stock Events

Stock Events

Advicenne 

$0
0
+$0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26MarExpected
Q2 2025
Q4 2025
-0.47
-0.14
0.2
0.53
Expected EPS
N/A
Actual EPS
N/A

Financials

-159.97%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
12.07MRevenue
-19.31MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADVVF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it develops and markets drugs for treating cystic fibrosis, a focus area that overlaps with Advicenne's work on kidney and metabolic disorders.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that has a broad portfolio, including treatments for chronic kidney disease, making it a competitor.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates in various therapeutic areas, including cardiovascular, renal, and metabolism, competing with Advicenne's products.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on rare genetic diseases, some of which affect metabolic processes similar to Advicenne's target disorders.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a diverse portfolio that includes treatments for bone and kidney diseases, areas that overlap with Advicenne's interests.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad range of products, including treatments for kidney diseases, competing in the same market as Advicenne.
Sanofi
SNY
Mkt Cap124.45B
Sanofi focuses on a wide array of therapeutic areas, including rare diseases, which puts it in competition with Advicenne.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a diverse pharmaceutical portfolio, including areas that compete with Advicenne's focus on kidney and metabolic disorders.

About

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Show more...
CEO
ISIN
FR0013296746

Listings

F
DE
3MM.F
Grey Market
US
ADVVF
PA
FR
ALDVI.PA

0 Comments

Share your thoughts

FAQ

What is Advicenne stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Advicenne stocks are traded under the ticker ADVVF.
When is the next Advicenne earnings date?▼
Advicenne is going to release the next earnings report on September 17, 2026.
What is Advicenne revenue for the last year?▼
Advicenne revenue for the last year amounts to 12.07M USD.
What is Advicenne net income for the last year?▼
ADVVF net income for the last year is -19.31M USD.
When did Advicenne complete a stock split?▼
The last stock split for Advicenne was on October 14, 2011 with a ratio of 1:4.